Skip to main content
. 2018 Dec 14;19(1):27–46. doi: 10.1007/s40268-018-0256-6

Fig. 4.

Fig. 4

Continuation status of suvorexant (safety analysis population). “Total” includes 63 patients in the “Others” category of Table 1